ArticleInternal medicine (Tokyo, Japan)2026
An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression.
Yoko Nakanishi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.